Houston experts talk tech and the city's future as an innovation hub

Eavesdropping in Houston

The Greater Houston Partnership hosted a panel of Houston tech experts for the second annual State of Technology event. GHP/Twitter

What's the future of technology in the Bayou City? Several experts sat down to discuss at a recent luncheon.

The Greater Houston Partnership hosted its second annual State of Technology event — the first to be hosted in person — this week, and panelists joined the stage to discuss ESG, venture capital, and what's next for Houston's growing tech scene. Missed the conversation? Here are several key moments from the event.

"We've got to keep our foot on the gas in Houston."

— Bob Harvey, president and CEO of the GHP, says at the start of the panel. "We were hardly in the game at all five years ago. We are clearly in the game today — we're being noticed," he continues. "But just being in the game is not what we aspire to. We aspire to be a leader and a major player, so we still have a lot of work to do."

"We have seen an incredible shift across all industries and sectors focused on the business impact of ESG. And Houston is in such an incredible place for that."

— Trinity Lloyd, sustainability and energy transition lead at Google Cloud. "Like technology, energy is at the core of every industry and sector," she shares. "We're seeing a ton of innovation around energy transition and climate tech."

"Venture capitalists are seeking the best ideas. Traditionally, VC has been about who you know, but that's changed drastically."

— Sandy Guitar, managing director of the HX Venture Fund. "We're not all the way there yet, but most venture capitalists we're working with are very focused on making sure they get the best ideas in the most democratic way," Guitar says of inclusion in VCs. "You really have to understand difference to solve important problems."

"Early stage venture is at its prime right now. ... It also happens to be the kind of environment that Houston has really been known for."

— Guitar says of the landscape of Houston's startup ecosystem. "We have great early stage venture capital opportunities," she says. "People are looking to get invested in earlier and earlier."

"Premium is now knowing where your products came from." 

— Ann Lai, vice president and general manager of displays solutions business group at HP Inc. "The progeny of your device or services is extremely important to the average user."

"While we seek to solve our own corporate social responsibility and innovate within our organizations to have better and more accurate reporting, we have this opportunity to create new markets."

— Lloyd says. "We're starting to see industry lines blurring," she continues. "In 10 years, the way we all do business is going to be different."

"How do we use all of us as grassroots ambassadors to talk about Houston as a strong place for technology?"

— Lai says on getting the word out about Houston's tech scene. "We also need to find ways to track talent earlier in the pipeline."

"It's about the venture capital community at large efficiently finding the fastest growing deals, and corporations having a risk tolerance to lean into that."

— Guitar says about what needs to happen in Houston. "It's about getting that match making right," "That can change the trajectory of Houston."

"Doing good in the world is critical to attracting talent."

— Lloyd says on the future of the workforce. "Houston has an infrastructure of intellectual capital unlike any other city in the world that is really critical across ESG and the climate spectrum."

Paying a per-employee fee, companies can give their team access to a one-stop-shop approach to medical care with Crossover. Courtesy of Crossover

California B2B medical care concept enters Houston market with HP Inc. already signed on as a client

One-stop shop

Information technology provider HP Inc. and other major employers in the Houston area are exploring a new way to offer medical care to their employees.

A California company called Crossover Health just opened a 5,300-square-foot medical clinic in Spring. The clinic — Crossover Health's first in the Houston area — enables several self-insured employers to share one provider of primary healthcare services for their employees in an effort to cut costs and promote convenience.

Aside from primary medical care, offerings at the Spring clinic include physical therapy, and chiropractic, acupuncture, and fitness services. Each employer pays a monthly per-employee fee for access to Crossover Health.

At the Spring center, Crossover Health seeks to act on its "belief that healthcare should be convenient, simple to navigate, affordable, and personalized."

The Spring location, at 28420 Hardy Toll Road, features four rooms for primary care, and two each for physical therapy, acupuncture, and health coaching. At the outset, the clinic employs 13 people, but more hires are planned as Crossover Health adds clients there.

Palo Alto, California-based HP is the only client of the Spring clinic that Crossover Health is permitted to identify. In February, HP moved about 2,400 employees into its new two-building, 12-acre campus at Springwoods Village, a master-planned community just west of the Crossover Health clinic. Later this year, San Jose, California-based Hewlett Packard Enterprise Co., a sister company of HP, is scheduled to kick off construction of a new campus at Springwoods Village.

Neighboring employers include ExxonMobil, Southwestern Energy, and the American Bureau of Shipping.

For employers, Crossover Health operates medical clinics that are at or near worksites. Outside the Houston area, Crossover Health's corporate clients include Apple, LinkedIn, and Visa.

Larry Boress, executive director of the Dallas-based National Association of Worksite Health Centers, says clinics like Crossover Health's can reduce travel time for employees heading to medical appointments and, as a result, can improve productivity.

"The value of a worksite health and wellness center for both large and small employers in Houston is that it offers the ability to gain real value on their healthcare investment," Boress says.

Aside from trimming healthcare costs, such centers can boost employee satisfaction and decrease absenteeism, he says.

"These centers have also been found to help employers be an employer of choice, benefiting recruitment and retention of employees," Boress says.

A 2018 survey by consulting firm Mercer and the National Association of Worksite Health Centers found that in 2017, one-third of U.S. employers with at least 5,000 employees provided worksite medical clinics, up from almost one-fourth in 2012.

A different survey — this one conducted in 2018 by the National Association of Worksite Health Centers and Benfield, a market research, strategy, and communications consulting firm that focuses on the healthcare industry — showed that among large employers with some sort of medical arrangement, 63 percent offered on-site clinics, 16 percent offered nearby clinics, and 21 percent offered a mix of the two.

"The hope with on-site or near-site clinics is to make healthcare more convenient for employees, and along the way ideally cheaper by cutting down on visits," Business Insider reported in 2018. "Crossover says it can save as much as $970 per member compared to what employers would be paying if that employee went through the traditional healthcare system. That savings can add up for a company with thousands of employees."

Crossover Health already has brought its brand of healthcare delivery to Austin and San Antonio. Now that the company has planted its flag in the Houston market, it's eyeing its first location in Dallas-Fort Worth.

"Texas, which has consistently ranked as the top U.S. state for business and job growth, is one of our most important markets as we continue to expand our national footprint," Dr. Scott Shreeve, co-founder and CEO of Crossover Health, says in a release. "The new Spring center allows us to introduce our new model of primary care to an increasing number of corporations moving to the Lone Star State."


features four rooms for primary care, and two each for physical therapy, acupuncture, and health coaching.Courtesy of Crossover Health

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings